Boston Scientific Corporation (NYSE: BSX) entered into a $2 billion accelerated share repurchase agreement with JPMorgan Chase Bank, National Association, the company announced. The transaction is part of Boston Scientific's previously announced $5 billion share repurchase authorization.

Under the agreement terms, Boston Scientific will pay $2 billion and receive common stock with an aggregate value of 80% of the repurchase price based on the closing share price as of May 15, 2026. This represents approximately 30.4 million shares based on the May 15, 2026 closing price of $52.68.

The total number of shares Boston Scientific will ultimately repurchase will be determined based on the volume-weighted average price of the company's common stock during the agreement term, less a discount and subject to adjustments pursuant to the agreement terms and conditions. The final settlement is expected to be completed by June 30, 2026.

Following completion of the accelerated share repurchase, Boston Scientific will have $3 billion remaining available under the share repurchase authorization.

The company stated the expected net impact to adjusted earnings per share from the accelerated share repurchase in full year 2026 is $0.02, which is accretive to Boston Scientific's previously issued guidance on April 22, 2026.

The information is based on a company press release statement.